In this episode, Dr Jin-Xiong She, a scientist with more than 400 publications, over 20,000 citations, and more than $100 million in research funding, explains why he left the top tier of academic medicine to pursue something more urgent: finding better ways to detect decline early and protect healthspan before disease takes hold. He shares what nearly 100,000 NAD tests have uncovered and why he believes biomarker baselines could change the way we think about prevention.https://www.jinfiniti.com/https://www.youtube.com/@ProfJinSheIn this episode:00:00 Welcome and Guest Intro01:47 From Genomics to Longevity04:18 T1D TEDDY Study Breakthroughs06:07 Leaving Academia for Impact07:37 Healthspan Over Lifespan10:09 TAO Test Act Optimise13:20 Choosing Actionable Biomarkers17:02 Why NAD Tops the List21:45 NAD Decline and Key Drivers25:21 Raising NAD Lifestyle vs Supplements27:51 Athletes' Inflammation and Low NAD31:54 Optimal NAD Range and Niacin Risks37:28 SubQ Injections vs Oral NMN Data41:42 Dosing and Cutting Useless Supplements43:52 Access Economics and Policy Ideas46:50 Industry Adoption and Big Names47:59 Supplement Market Problems50:17 Rapid Fire and Closing Takeaways52:04 Final Summary and Goodbye